Galectin
Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.
Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans. Galectins are usually classified into three groups based on their structure: (i) prototypical galectins (galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal 13, Gal14, and Gal15), characterized by a single CRD, which can act as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), with a single CRD and a large amino-terminal domain that facilitates the formation of oligomers; (iii) the tandem repeat galectins, with two CRDs that are linked through a small peptide domain; this group includes Gal4, Gal6, Gal8, Gal9, and Gal12. Recently, Galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies.
Galectin Isoform Specific Products
All Product Categories
-
Galectin Related Products (50)
Related Products (50)
-
Antibodies (7)
-
Galectin Isoform Comparison
-
Galectin-3-IN-2
0 ImagesCat. No.: HY-144313CAS No.: 2883648-71-1Galectin-3-IN-2 (Compound 9) is a potent multivalent inhibitor of galectin-3 (Gal-3; IC50=8.3 μM). Galectin-3 participates in many cancer-related metabolic processes.
-
Galectin-3-IN-6
0 ImagesCat. No.: HY-173235CAS No.: 2604662-64-6Galectin-3-IN-6 is a human and murine galectin-3 (Gal-3) inhibitor, with an IC50 of 12 nM against human galectin-3, an IC50 of 12.6 nM against mutant murine galectin-3 (V160A), and a Kd of 13 nM for human galectin-3, as well as oral bioavailability. Galectin-3-IN-6 reduces the levels of liver fibrosis markers type I collagen and α-smooth muscle actin in mouse models of acute liver injury and fibrosis. Galectin-3-IN-6 can be used for the research of acute liver injury and fibrosis.
-
SNAP 398299
0 ImagesCat. No.: HY-123708CAS No.: 903878-06-8SNAP 398299 is a Gal3 receptor antagonist with potential anxiolytic and antidepressant effects. SNAP 398299 can partially reverse the neuropeptide Galanin-induced inhibition of dorsal raphe cell firing and the Galanin-induced hyperpolarizing current.
-
Galectin-3 antagonist 2
0 ImagesCat. No.: HY-146809CAS No.: 2921603-02-1Galectin-3 is a β Galactoside specific carbohydrate recognition protein (lectin) has the ability to promote the migration of B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and withstand drug research.
-
Galectin-3-IN-3
0 ImagesCat. No.: HY-163405CAS No.: 2491661-50-6Galectin-3-IN-3 (Compound 4) is an orally active and selective inhibitor of Gal-3, with IC50 values of 11 nM and 84 nM against mGal-3 and hGal-3 respectively.
-
CHI3L1-IN-6
0 ImagesCat. No.: HY-180937CAS No.: 1914772-75-0CHI3L1-IN-6 (Compound 9e) is a CHI3L1 inhibitor with a Kd of 19.11 μM for hCHI3L1. CHI3L1-IN-6 blocks CHI3L1-Galectin-3 interaction. CHI3L1-IN-6 reduces STAT3 signaling. CHI3L1-IN-6 exhibits anti-cancer activity against glioblastoma.
-
F3-PEG8-RiboTAC
0 ImagesCat. No.: HY-176259F3-PEG8-RiboTAC is a RiboTAC that can specifically degrade the mRNA of the oncogene LGALS1. F3-PEG8-RiboTAC can induce tumor cell apoptosis and inhibit invasion. F3-PEG8-RiboTAC has anti-tumor activity and can be used in the research of tumors such as leukemia and triple-negative breast cancer. (RNase L ligand (HY-177030); RNA binder (HY-177031); Linker (HY-W019798)).
-
Galectin-3-IN-5
0 ImagesCat. No.: HY-162789Galectin-3-IN-5 (Compound 20) is an orally active inhibitor of galectin-3 (Gal-3), with an IC50 value of 9.2 nM against hGal-3.
-
Galectin-8N-IN-2
0 ImagesCat. No.: HY-163900CAS No.: 3055149-84-0Galectin-8N-IN-2 (compound 2) is a potent and selective Galectin-8N inhibitor with a Ki value of 74 μM.
-
4A-MPLA ammonium
0 ImagesCat. No.: HY-N16021CAS No.: 2260669-09-64A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis.
